全球疫苗市場:2013年為止的預測

全球疫苗市場:2013年為止的預測 是由出版商RNCOS E-Services Pvt. Ltd.在2011年11月所出版的。 這份英文市場調查報告書包含140 Pages 價格從美金1500起跳。

簡介

疫苗是醫療領域收益性及成長性最高的商務部門之一。2011年全球市場規模為276億美金，但預計到2013年將擴大到330億美金。

ワクチンは医療分野で最も収益性と成長性の高いビジネス部門のひとつとなっております。2011年の世界市場の規模は276億米ドルでしたが、2013年には330億米ドルにまで拡大すると予想されています。 当レポートでは、世界のワクチン市場について分析し、全体的な市場構造や最新の技術・市場動向、各地域の市場動向詳細、市場促進・抑制要因、主要企業プロファイルといった情報を盛り込んで、概略以下の構成でお届けします。

本報告提供全球疫苗市場相關分析，整體市場結構和最新技術、市場趨勢，各地區市場趨勢詳細內容，推動及阻礙市場要素，再加上主要企業簡介等資訊彙整，為您概述為以下內容。

第1章 分析師的見解

第2章 分析方法

第3章 市場概況

第4章 主要市場推動因素

• 定期的疫苗接種率提高
• 新市場
• 技術開發
• 疫苗研究的投資

第5章 新趨勢

• DNA疫苗的普及化
• 疫苗市場的企業合併與收購
• 疫苗流通的改善

第6章 兒童用疫苗

• 肺炎球菌疫苗
• 小兒麻庳疫苗
• 水痘疫苗
• 腦膜炎疫苗
• 輪狀病毒疫苗
• DTP疫苗
• MMR(三合一)疫苗
• 結核疫苗

第7章 成人、出國者、治療用疫苗

• B型肝炎疫苗
• 瘧疾疫苗
• 黃熱病疫苗
• 狂犬病(恐水症)疫苗
• 日本腦炎疫苗
• 傷寒症疫苗
• 西尼羅病毒疫苗
• HIV疫苗
• 癌症疫苗
• 流感疫苗

第8章 主要的地區市場

• 美國
  • 市場概況
  • 主要企業
  • 產品組成
• 歐洲
  • 市場概況
  • 主要企業
  • 產品組成
• 中國
  • 市場概況
  • 主要企業
  • 產品組成
• 印度
  • 市場概況
  • 主要企業
  • 產品組成
• 日本
  • 市場概況
  • 主要企業
  • 產品組成
• 巴西
  • 市場概況
  • 主要企業
  • 產品組成

第9章 疫苗產業的阻礙因素

• 高額的研究開發費用
• 臨床實驗、製造用基本設備的不足
• 疫苗的供給
• 非效率的流通

第10章 競爭環境

• Sanofi-Aventis
• Novartis
• GSK
• Pfizer
• Merck & Co.

圖表一覽

目錄

Abstract

Vaccine represents one of the most attractive and fast growing sectors, with players' revenue exceeding their expectations. The global vaccine market is primarily divided into adult and pediatric segments, further classified into several other sub-segments. Both the adult and pediatric vaccine sectors have sustained the growth momentum and industry participants have been devising strategies to enlarge their presence in these segments.

According to our new research report, " Global Vaccine Market Forecast to 2013" , the global vaccine market is likely to reach an amount worth to US$ 27.6 Billion by the end of 2011, on the back of key factors, such as high growth in emerging markets, technological advancements, strong support from government, and other active associations like WHO and GAVI and increased investment in research activities. With the successful launch of new vaccines in the coming years for key indications, the market for vaccines may further exhibit good performance and it is estimated that the market will reach to the mark of US$ 33 Billion by 2013.

Our analysis of the global vaccine market illustrates that a large number of players are spending huge amount on the aspect of research and development. This is mainly due to the fact that the successful launch of very first vaccine products for any virus may significantly impact the market share. Currently, the companies are actively participating in the trials of vaccines for cancer, malaria, tuberculosis, HIV/AIDS, among others.

The report " Global Vaccine Market Forecast to 2013" , provides an in-depth analysis of the global vaccine market by focusing on key countries of the world. It investigates the current market trends and analyzes their impact on the overall market performance in a broad way. Moreover, the report identifies all the necessary factors and aspects related to market and represent current industry status with future forecast on vaccine types and countries for 2010-2013. In addition, the description of key players and their recent activities have been provided to showcase an effective and balanced outlook of the global vaccine market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Overview

4. Key Market Drivers

• 4.1 Improved Routine Immunization
• 4.2 Emerging Markets
• 4.3 Technological Developments
• 4.4 Investment in Vaccine Research

5. Emerging Trends

• 5.1 DNA Vaccines: Gaining Popularity
• 5.2 M&As in Vaccine Market
• 5.3 Vaccine Delivery Advancements

6. Pediatric Vaccines

• 6.1 Pneumococcal
• 6.2 Polio
• 6.3 Varicella
• 6.4 Meningococcal
• 6.5 Rotavirus
• 6.6 DTP
• 6.7 Measles, Mumps & Rubella (MMR)
• 6.8 Tuberculosis

7. Adult/Travel & Therapeutic Vaccines

• 7.1 Hepatitis B
• 7.2 Malaria
• 7.3 Yellow Fever
• 7.4 Rabies
• 7.5 Japanese Encephalitis
• 7.6 Typhoid
• 7.7 West Nile
• 7.8 HIV
• 7.9 Cancer
• 7.10 Influenza

8. Key Geographical Markets

• 8.1 US
  • 8.1.1 Market Overview
  • 8.1.2 Key Players
  • 8.1.3 Product Portfolio
• 8.2 Europe
  • 8.2.1 Market Overview
  • 8.2.2 Key Players
  • 8.2.3 Product Portfolio
• 8.3 China
  • 8.3.1 Market Overview
  • 8.3.2 Key Players
  • 8.3.3 Product Portfolio
• 8.4 India
  • 8.4.1 Market Overview
  • 8.4.2 Key Players
  • 8.4.3 Product Portfolio
• 8.5 Japan
  • 8.5.1 Market Overview
  • 8.5.2 Key Players
  • 8.5.3 Product Portfolio
• 8.6 Brazil
  • 8.6.1 Market Overview
  • 8.6.2 Key Players
  • 8.6.3 Product Portfolio

9. Restraints in Vaccine Industry

• 9.1 High R&D Cost
• 9.2 Lack of Infrastructure for Trials and Manufacturing
• 9.3 Vaccine Supply
• 9.4 Ineffective Distribution

10. Competitive Landscape

• 10.1 Sanofi-Aventis
• 10.2 Novartis
• 10.3 GSK
• 10.4 Pfizer
• 10.5 Merck & Co.

List of Figures:

• Figure 3-1: Global - Vaccine Market (Billion US$), 2010-2013
• Figure 4-1: Global - Vaccine R&D Investment by Region (%), 2010
• Figure 5-1: Global - Key M&As in Vaccine Market (2005-2010)
• Figure 6-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
• Figure 6-2: Global - Pneumococcal Vaccine Market (Billion US$), 2010-2013
• Figure 6-3: Global - Number of Polio Incidences (2007-2010)
• Figure 6-4: Global - Polio Vaccine Market (Billion US$), 2010-2013
• Figure 6-5: Global - Varicella Vaccine Market (Billion US$), 2010-2013
• Figure 6-6: Global - Meningococcal Vaccine Market (Million US$), 2010-2013
• Figure 6-7: Global - Rotavirus Vaccine Market (Million US$), 2010-2013
• Figure 6-8: Global - Rotavirus Vaccine Market by Region (%), 2010
• Figure 6-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
• Figure 6-10: Global - Number of Ntetanus Incidences by Region (2009 & 2010)
• Figure 6-11: Global - Number of Ttetanus Incidences by Region (2009 & 2010)
• Figure 6-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
• Figure 6-13: Global - Number of Measles Incidences by Region (2009 & 2010)
• Figure 6-14: Global - Number of Mumps Incidences by Region ('000), 2009 & 2010
• Figure 6-15: Global - Number of Rubella Incidences by Region (2009 & 2010)
• Figure 6-16: Global - Number of Tuberculosis Incidences by Region (2008 & 2009)
• Figure 7-1: Global - Hepatitis B Surface Antigen Prevalence (%)
• Figure 7-2: Global - Hepatitis B Vaccine Market (Billion US$), 2010-2013
• Figure 7-3: Global - Malaria Vaccines under Pipeline
• Figure 7-4: Global - Yellow Fever Vaccine Market (Million US$), 2010 & 2013
• Figure 7-5: Global - Japanese Encephalitis Market (Million US$), 2010-2013
• Figure 7-6: Global - R&D Investment in AIDS Vaccine Development (Million US$), 2006-2009
• Figure 7-7: Global - Sources for Funding in HIV Vaccine R&D (%), 2009
• Figure 7-8: Global - Cancer Vaccine Market (Billion US$), 2010-2013
• Figure 7-9: Global - Seasonal Influenza Vaccine Market (Billion US$), 2010-2013
• Figure 8-1: Global - Vaccine Market by Region (%), 2010
• Figure 8-2: Global - Forecast for Vaccine Market by Region (%), 2013
• Figure 8-3: US - Vaccine Market (Billion US$), 2010-2013
• Figure 8-4: US - Share of Key Players in Vaccine Market (2010)
• Figure 8-5: US - Pediatric Vaccine Market (Billion US$), 2010-2013
• Figure 8-6: US - Adult Vaccine Market (Billion US$), 2010-2013
• Figure 8-7: US - Hepatitis Vaccine Market (Billion US$), 2010-2013
• Figure 8-8: US - Share of Key Players in Seasonal Influenza Vaccine Production (2010-2011)
• Figure 8-9: US - Seasonal Influenza Vaccine Production and Consumption (Million Doses), 2006-07 to 2010-11
• Figure 8-10: US - Seasonal Influenza Vaccine Market (Billion US$), 2010-2013
• Figure 8-11: Europe - Vaccine Market (Billion US$), 2010-2013
• Figure 8-12: Europe - Share of Key Players in Vaccine Market (2008)
• Figure 8-13: China - Vaccine Market (Billion RMB), 2010-2013
• Figure 8-14: China - Share of Key Players in Vaccine Market (2008)
• Figure 8-15: China - Influenza Vaccine Market (Million US$), 2010-2013
• Figure 8-16: India - Share of Domestic Consumption and Exports in Vaccine Market (2010)
• Figure 8-17: India - Vaccine Market (Million US$), 2010-2013
• Figure 8-18: India - Share of Key Players in Vaccine Market (2010)
• Figure 8-19: Japan - Vaccine Market (Billion US$), 2010-2013
• Figure 8-20: Japan - Seasonal Influenza Vaccine Market (Million US$), 2010-2013
• Figure 8-21: Japan - Share of Domestic and Foreign Players in Vaccine Market (2009)
• Figure 8-22: Brazil - Vaccine Market (Billion BRL), 2010-2013
• Figure 8-23: Brazil - Share of Public and Private Sector in Vaccine Market
• Figure 8-24: Brazil - Share of Key Players in Private Sector Vaccine Market (2008)
• Figure 9-1: Global - Dose Consumption and Revenue by Regional Income (%)
• Figure 10-1: Global - Share of Key Players in Vaccine Market (2009)

List of Tables:

• Table 3-1: Global - Production Method for Key Vaccines
• Table 4-1: Global - Key Health Indicators by Income Classification
• Table 5-1: Global - Recent Deals between Key Western Vaccine Manufacturers and Companies in Emerging Markets
• Table 5-2: Global - Key Intradermal Delivery Devices
• Table 6-1: Global - Leading DTP Vaccine Brands (Million US$), 2008
• Table 6-2: Global - Leading MMR Vaccine Brands (Million US$), 2008
• Table 6-3: Global - Tuberculosis Vaccines under Pipeline (2010)
• Table 7-1: Global - Number of HIV/AIDS Patients by Region (2009)
• Table 7-2: Global - HIV Vaccines under Pipeline
• Table 7-3: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
• Table 7-4: Global - Cancer Vaccines under Pipeline (2009)
• Table 7-5: Global - Top 5 Companies' Pandemic Influenza (H1N1) Vaccine Sales (Million US$), 2009
• Table 8-1: China - Number of Reported Cases of Diseases Preventable by Vaccine (2008 & 2009)
• Table 8-2: China - Vaccine Classification
• Table 8-3: China - Annual Pediatric Vaccine Doses Requirement (Million Doses)
• Table 8-4: Japan - Sales of Top Domestic Vaccine Manufacturers (Million JPY)
• Table 9-1: Health Statistics in Developed and Developing Countries (%)
• Table 10-1: Sanofi Aventis - Strengths and Weaknesses
• Table 10-2: Novartis - Strengths and Weaknesses
• Table 10-3: GSK - Strengths and Weaknesses
• Table 10-4: Pfizer - Strengths and Weaknesses

相關商品